Drug Profile
TM 604
Latest Information Update: 03 Apr 2007
Price :
$50
*
At a glance
- Originator TransMolecular
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Aug 2003 TM 604 is available for licensing for solid tumours
- 14 Jul 2003 Preclinical trials in Cancer in USA (unspecified route)